Skip to main content
Assets
Hims & Hers Health logo
HIMS.NYSE
Hims & Hers Health
Health Care · Health Care Services
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany.MoreShow less
HQ: United StatesListed: United States

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for Hims & Hers Health.

Historical AI Forecasts

Hims Hers Health Inc (HIMS.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 11 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 3 May 2026Deep analysis 3 May 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
Superintelligence AI advisor icon

Superintelligence AI

The Anthropologist FrameworkAI Thinker

Model rating

Buy

5-Year Return Est.

+147.6%

HIMS.NYSE does not currently pay dividends

1. Investment Thesis — Base Case

The Base Case projects a rocky but ultimately highly lucrative civilizational ascent for HIMS. The 2026 macro shock (energy blockades, ) and regulatory noise (, FDA posturing) will cause extreme near-term volatility and elevated churn in their most discretionary segments. However, the core thesis holds: humans will continue to pay a premium to bypass the horrific UX of the traditional medical system. HIMS successfully pivots the majority of its base into proprietary, personalized compounds that evade federal price floors.

  • Near-term (2026): Volatile trading as the market digests regulatory threats and consumer wallet compression.
  • Mid-term (2027-2028): Cash flow compounding becomes undeniable. HIMS navigates the end of shortages by locking in authorized generic partnerships.
  • Long-term (2029+): HIMS establishes itself as a dominant digital primary care node for the millennial/Gen-Z demographic, operating as a negentropy engine that reliably extracts high margins from human vanity and wellness optimization. The stock price compounds steadily upward to reflect its structural .

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.-3.2716.1435.5454.9474.34Apr 2021Oct 2023Apr 2026Oct 2028May 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2021-04-2712.05
Observed price2021-05-138.16
Observed price2021-05-2112.81
Observed price2021-06-0614.51
Observed price2021-06-1811.10
Observed price2021-06-2210.90
Observed price2021-07-169.13
Observed price2021-07-208.69
Observed price2021-08-018.02
Observed price2021-08-176.91
Observed price2021-09-108.71
Observed price2021-09-148.66
Observed price2021-10-047.24
Observed price2021-10-247.82
Observed price2021-11-058.33
Observed price2021-11-098.28
Observed price2021-12-035.88
Observed price2021-12-116.03
Observed price2021-12-236.65
Observed price2022-01-046.50
Observed price2022-01-284.32
Observed price2022-02-214.25
Observed price2022-02-255.30
Observed price2022-03-134.09
Observed price2022-03-255.17
Observed price2022-04-025.37
Observed price2022-04-224.65
Observed price2022-04-264.65
Observed price2022-05-123.20
Observed price2022-05-243.42
Observed price2022-06-174.35
Observed price2022-06-214.38
Observed price2022-07-075.61
Observed price2022-07-195.74
Observed price2022-08-127.15
Observed price2022-08-166.96
Observed price2022-08-205.99
Observed price2022-09-136.04
Observed price2022-09-255.32
Observed price2022-10-115.05
Observed price2022-10-194.09
Observed price2022-11-085.53
Observed price2022-12-026.61
Observed price2022-12-147.19
Observed price2022-12-266.28
Observed price2023-01-076.24
Observed price2023-01-277.75
Observed price2023-02-047.87
Observed price2023-02-249.77
Observed price2023-02-2811.27
Observed price2023-03-128.92
Observed price2023-04-059.77
Observed price2023-04-2111.68
Observed price2023-05-0711.91
Observed price2023-05-199.77
Observed price2023-05-239.20
Observed price2023-06-168.65
Observed price2023-06-208.35
Observed price2023-07-029.21
Observed price2023-07-189.11
Observed price2023-08-117.20
Observed price2023-08-157.18
Observed price2023-09-086.53
Observed price2023-09-126.46
Observed price2023-09-246.08
Observed price2023-10-305.78
Observed price2023-11-036.48
Observed price2023-11-116.87
Observed price2023-12-018.83
Observed price2023-12-178.58
Observed price2023-12-298.90
Observed price2024-01-029.64
Observed price2024-01-188.42
Observed price2024-02-038.77
Observed price2024-02-1510.05
Observed price2024-02-2713.43
Observed price2024-03-2216.33
Observed price2024-03-2615.82
Observed price2024-04-1911.90
Observed price2024-05-0511.52
Observed price2024-05-1714.57
Observed price2024-05-2517.43
Observed price2024-06-1423.8
Observed price2024-06-1824.8
Observed price2024-07-0820.5
Observed price2024-07-1623.1
Observed price2024-08-0915.96
Observed price2024-08-2116.57
Observed price2024-09-0613.65
Observed price2024-09-1014.53
Observed price2024-09-3018.42
Observed price2024-10-0818.75
Observed price2024-10-2823.1
Observed price2024-11-1720.4
Observed price2024-11-2932.2
Observed price2024-12-0733.7
Observed price2024-12-1926.4
Observed price2024-12-3124.2
Observed price2025-01-2430.9
Observed price2025-01-2831.5
Observed price2025-02-1359.2
Observed price2025-03-0143.6
Observed price2025-03-1331.5
Observed price2025-03-2537.0
Observed price2025-04-1026.8
Observed price2025-04-2225.4
Observed price2025-05-1664.7
Observed price2025-05-2061.2
Observed price2025-06-0552.8
Observed price2025-06-1759.2
Observed price2025-06-2541.4
Observed price2025-07-1949.5
Observed price2025-07-3166.2
Observed price2025-09-0141.7
Observed price2025-09-0548.4
Observed price2025-09-0947.8
Observed price2025-09-2959.1
Observed price2025-10-1562.8
Observed price2025-10-3145.5
Observed price2025-11-0442.8
Observed price2025-11-2033.6
Observed price2025-12-0639.2
Observed price2025-12-2634.3
Observed price2026-01-0735.5
Observed price2026-01-2329.6
Observed price2026-01-2729.7
Observed price2026-02-2015.63
Observed price2026-02-2815.17
Observed price2026-03-1624.9
Observed price2026-03-2819.18
Observed price2026-04-1728.8
Observed price2026-04-2530.2
Observed price2026-05-1525.1
Observed price2026-05-1922.4
Observed price2026-06-0428.0
Observed price2026-06-1631.5
Observed price2026-07-0638.3
Observed price2026-07-1435.1
Observed price2026-07-3027.0
Observed price2026-08-2332.0
Observed price2026-09-0427.7
Observed price2026-09-1428.8
Observed price2026-09-1527.9
Observed price2026-09-1828.0
Published advisor forecast2026-05-0127.4
Published advisor forecast2026-08-0126.0
Published advisor forecast2026-11-0128.1
Published advisor forecast2027-02-0130.9
Published advisor forecast2027-05-0129.7
Published advisor forecast2027-08-0133.3
Published advisor forecast2027-11-0130.6
Published advisor forecast2028-02-0135.2
Published advisor forecast2028-05-0138.0
Published advisor forecast2028-08-0140.3
Published advisor forecast2028-11-0142.3
Published advisor forecast2029-02-0145.3
Published advisor forecast2029-05-0142.5
Published advisor forecast2029-08-0146.8
Published advisor forecast2029-11-0152.4
Published advisor forecast2030-02-0156.6
Published advisor forecast2030-05-0153.8
Published advisor forecast2030-08-0157.0
Published advisor forecast2030-11-0161.6
Published advisor forecast2031-02-0164.6
Published advisor forecast2031-05-0167.9

2. Scenarios & Signals

Bull case

In the Bull Case, the regulatory environment unexpectedly favors HIMS. The FDA permits continued compounding or HIMS lands an exclusive partnership for a novel oral . The breaks early, releasing spend.

  • Amazon Clinic's interface proves too generic, failing to capture the lifestyle brand loyalty HIMS has built.
  • HIMS leverages its massive data node to cross-sell longevity and specialized diagnostic subscriptions, driving LTV to unprecedented heights.
  • The market applies a software-like multiple to its compounding healthcare revenue, driving the stock toward a $90+ valuation.

Bear case

The Bear Case materializes if the macro and regulatory vectors form a lethal convergence. The FDA ruthlessly closes all compounding loopholes under Big Pharma lobbying pressure, instantly vaporizing HIMS's highest-growth vector.

  • Sustained forces mass cancellations of hair-loss and ED subscriptions as consumers prioritize caloric survival.
  • sets brutal price floors that reset consumer expectations, destroying HIMS's margin on non-compounded generics.
  • Amazon captures the remains. The equity acts as a civilizational short, decaying toward irrelevance and a sub-$10 fire sale.

Current crowd narrative

The noisy, narrative-addicted crowd views HIMS as a pandemic-era digital fad that artificially resuscitated itself by exploiting legal loopholes to peddle bootleg Ozempic. The prevailing consensus is that HIMS is trapped: squeezed from below by forcing generic prices to the floor, squeezed from above by Eli Lilly deploying lawyers to shut down compounding, and flanked by Amazon Clinic. Sell-side analysts treat the recent price collapse to $27 as proof that the business model is structurally flawed and destined to revert to a low-margin mail-order pharmacy.

Alpha-gap assessment

The market chronically misprices UX friction and psychological resistance. The is that HIMS is not a pharmacy; it is a high-negentropy behavioral modification engine. The crowd focuses on the commodity (the pill) while ignoring the delivery system (the proprietary multi-ingredient compounds and the discrete, asynchronous interface). While targets the commodity, HIMS is moving its subscriber base into personalized formulations that break the generic pricing paradigm. The market is pricing HIMS as a regulatory arbitrageur, blinding itself to the underlying physics: HIMS is one of the few digital health platforms producing accelerating with deeply sticky cohorts.

Convergence catalyst

The will close when HIMS reports consecutive quarters of accelerating and stable in late 2026 and early 2027, proving explicitly that the rollout of and Amazon Clinic failed to degrade their core personalized compounding revenue. Validation of their non- compounding growth will force a multiple rerating.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus